GenSpera to Present at Rodman & Renshaw 17th Annual Global Investment Conference
(firmenpresse) - SAN ANTONIO, TX -- (Marketwired) -- 08/24/15 -- GenSpera, Inc. (OTCQB: GNSZ) announced today that Craig A. Dionne, Ph.D., chairman and chief executive officer at GenSpera, will present at Rodman & Renshaw''s 17th Annual Global Investment Conference on Wednesday, September 9, 2015 from 10:50 to 11:15 AM in Library (2nd floor), St. Regis Hotel, New York City.
Dr. Dionne stated, "I look forward to presenting interim data on our Glioblastoma Phase II trials, in addition to GenSpera''s corporate partnership progress during . This conference always draws sophisticated private investors, key leaders in the biopharmaceutical space and potential partners. I look forward to presenting to such a targeted audience."
Dr. Dionne''s presentation will be webcast. To listen to the presentation which, will be archived for 90 days please use the following link:
Mipsagargin is a prodrug in human clinical trials for several different tumor types. Mipsagargin consists of a thapsigargin derivative, 12ADT, coupled to a peptide that helps solubilize the prodrug and prevents its internalization into cells until the peptide is removed. The mechanism of action targets the enzyme PSMA, which is highly expressed on the surface of almost all cancer tumor vasculature, including those of glioblastoma. PSMA recognizes and removes the peptide, releasing the active ingredient 12ADT into the cell and bringing about cell death. The prodrug delivery system ensures that mipsagargin is activated only within the tumor, thus providing greater anti-tumor efficacy and minimizing side effects.
GenSpera, Inc. is a San Antonio-based biotech company that unlocks conventional thinking to conceive, design, and develop cancer therapies. GenSpera''s technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a patented prodrug delivery system that provides for targeted release of drug candidates within tumors. GenSpera''s lead drug candidate, mipsagargin, was granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) in 2013 for evaluation in patients with hepatocellular carcinoma (liver cancer).
For additional information on GenSpera, visit and connect on , , , and .
This communication may contain forward-looking statements. Investors are cautioned that statements in this document regarding potential applications of GenSpera''s technologies or the future prospects of the company constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights and the acceptance of GenSpera''s proposed therapies by the health community. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera''s periodic reports filed with the Securities and Exchange Commission.
Sean Leous
+1-646-683-8998
Adam Holdsworth
+1-646-862-4607
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 24.08.2015 - 06:30 Uhr
Sprache: Deutsch
News-ID 1380822
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
SAN ANTONIO, TX
Phone:
Kategorie:
Alternative
Anmerkungen:
Diese Pressemitteilung wurde bisher 186 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"GenSpera to Present at Rodman & Renshaw 17th Annual Global Investment Conference
"
steht unter der journalistisch-redaktionellen Verantwortung von
GenSpera Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
